by helios » Fri Jul 17, 2020 12:10 pm
Been doing some readings on $HTBX small caps no doubt for speculative play (bet).
This counter popped up as some were writing that it (or its -covid-gp64) would be acquired by $MRNA, which i find it amazingly interesting hypothesis as both are different modalities to even speak off! Anyway, I dived and looked at its management team and affiliates linkages they have wrt. Miami collaborations and resources, the announcement they made (see below). And the relationships built to-date wrt. their CMO partner Waisman Biomanufacturing to tech transfer in early August (??). Need to check if they are in the warps-speed-op. Need to check why there is a rumour with $MRNA. Nonetheless, the institutional players are jumping in with a higher % of institutional buyers now. Need to check their current float. ..................... and their trajectory to use their gp64 platform on NSCLC and re-divest onto covid is to prove their platform value as per any others, is definitely a gamification means ....................
So, at the right time, i may just dip in a small speculative amount ... believe under $2/- value ~ as a hedge if later, I will buy $MRNA or $NVAX Puts ..........
***************************************************************************************************************************************************************************************************
On March 2, 2020, we filed a provisional patent application that applies our immune system activating technology for treating or preventing
infection with the SARS-CoV-2 virus that causes coronavirus disease 2019 (COVID-19). An additional provisional patent application
utilizing OX40L in combination with our gp96 platform for treating or preventing COVID-19 was also filed on March 2, 2020.
On March 3, 2020, we issued a press release announcing that we have formally launched a program to develop a vaccine using our immune
activating gp96 vaccine platform for treating or preventing infection from the SARS-CoV-2 coronavirus that causes COVID-19.
On March 4, 2020, we entered into a collaboration with the University of Miami Miller School of Medicine to support the development of a
vaccine leveraging our gp96 therapeutic technology designed to target the SARS-CoV-2 coronavirus that causes COVID-19